Analysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) PT at $26.00

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have earned an average rating of “Buy” from the seven analysts that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $26.00.

Several equities analysts have recently commented on the company. Morgan Stanley reiterated an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Finally, Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $17.14 on Thursday. The stock has a market cap of $2.26 billion, a P/E ratio of -11.20 and a beta of 1.54. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a 50 day moving average of $16.45 and a 200-day moving average of $16.29. Centessa Pharmaceuticals has a 52 week low of $7.75 and a 52 week high of $19.09.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $17.44, for a total value of $959,200.00. Following the sale, the chief executive officer now directly owns 520,661 shares of the company’s stock, valued at $9,080,327.84. This trade represents a 9.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CTO Tia L. Bush sold 17,813 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $18.00, for a total value of $320,634.00. Following the completion of the sale, the chief technology officer now directly owns 147,615 shares in the company, valued at $2,657,070. This represents a 10.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 353,310 shares of company stock valued at $5,917,155 over the last three months. Company insiders own 11.59% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at $31,000. GAMMA Investing LLC increased its holdings in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares during the period. Barclays PLC increased its holdings in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at $171,000. 82.01% of the stock is owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.